FDA's Biosimilar Strategy Will Rely On "Fingerprint" Technology To Limit Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
European experiences with "totality of the evidence" method also seem to be shaping policy, according to FDA article in NEJM.